Crossref
‘Damning’ FDA inspection report undermines Alzheimer’s drug
Science · 2024
DOI: 10.1126/science.adp1964 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, 2024. Verfasst von Charles Piller. Hauptthemen laut MEDLINE: Alzheimer Disease, Scientific Misconduct, Spiro Compounds, United States Food and Drug Administration. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Themen: Demenz
Abstract (Originalsprache)
Inspectors faulted analyses of clinical trial samples by Hoau-Yan Wang for drug developer Cassava Sciences
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Alzheimer DiseaseScientific MisconductSpiro CompoundsUnited States Food and Drug AdministrationHumansUnited StatesClinical Trials as Topic
Substanzen
SimufilamSpiro Compounds
Zitieren
APA
Piller, C. (2024). ‘Damning’ FDA inspection report undermines Alzheimer’s drug. Science. https://doi.org/10.1126/science.adp1964
Vancouver
Piller C. ‘Damning’ FDA inspection report undermines Alzheimer’s drug. Science. 2024. doi:10.1126/science.adp1964
BibTeX
@article{Piller2024,
author = {Piller, Charles},
title = {‘Damning’ FDA inspection report undermines Alzheimer’s drug},
journal = {Science},
year = {2024},
doi = {10.1126/science.adp1964}
}
EUVIMED